Sec Form 4 Filing - Bujarski Robert Joseph @ QUIDEL CORP /DE/ - 2022-05-27

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bujarski Robert Joseph 2. Issuer Name and Ticker or Trading Symbol QUIDEL CORP /DE/ [ QDEL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) 9975 SUMMERS RIDGE ROAD 3. Date of Earliest Transaction (MM/DD/YY) 05/27/2022 (Street) SAN DIEGO, CA92121 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/27/2022 D( 1 ) 29,164 D 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Non-Qualified Stock Options $ 23.41 05/27/2022 D( 2 ) 8,798 ( 3 ) 02/05/2025 Common Stock 8,798 $ 0 0 D Non-Qualified Stock Options $ 15.4 05/27/2022 D( 2 ) 17,596 ( 3 ) 02/10/2026 Common Stock 17,596 $ 0 0 D Non-Qualified Stock Options $ 21.08 05/27/2022 D( 2 ) 14,343 ( 3 ) 02/15/2027 Common Stock 14,343 $ 0 0 D Non-Qualified Stock Options $ 46.41 05/27/2022 D( 2 ) 9,212 ( 3 ) 01/16/2028 Common Stock 9,212 $ 0 0 D Non-Qualified Stock Options $ 59.12 05/27/2022 D( 2 ) 7,246 ( 4 ) 02/04/2029 Common Stock 7,246 $ 0 0 D Non-Qualified Stock Options $ 77.16 05/27/2022 D( 2 ) 6,641 ( 5 ) 02/03/2030 Common Stock 6,641 $ 0 0 D Non-Qualified Stock Options $ 159.39 05/27/2022 D( 2 ) 2,935 ( 6 ) 09/14/2030 Common Stock 2,935 $ 0 0 D Non-Qualified Stock Options $ 254 05/27/2022 D( 2 ) 3,514 ( 7 ) 02/01/2031 Common Stock 3,514 $ 0 0 D Non-Qualified Stock Options $ 103.36 05/27/2022 D( 2 ) 12,876 ( 8 ) 01/31/2032 Common Stock 12,876 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 3,623 ( 11 ) ( 11 ) Common Stock 3,623 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 2,749 ( 12 ) ( 12 ) Common Stock 2,749 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 824 ( 12 ) ( 12 ) Common Stock 824 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 1,033 ( 13 ) ( 13 ) Common Stock 1,033 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 3,320 ( 14 ) ( 14 ) Common Stock 3,320 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 1,052 ( 12 ) ( 12 ) Common Stock 1,052 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 315 ( 12 ) ( 12 ) Common Stock 315 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 941 ( 15 ) ( 15 ) Common Stock 941 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 1,351 ( 12 ) ( 12 ) Common Stock 1,351 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 405 ( 12 ) ( 12 ) Common Stock 405 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 2,637 ( 16 ) ( 16 ) Common Stock 2,637 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 1,559 ( 17 ) ( 17 ) Common Stock 1,559 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 12,878 ( 18 ) ( 18 ) Common Stock 12,878 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 13,545 ( 19 ) ( 19 ) Common Stock 13,545 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 1,190 ( 12 ) ( 12 ) Common Stock 1,190 $ 0 0 D Restricted Stock Units ( 9 ) 05/27/2022 D( 10 ) 357 ( 12 )( 20 ) ( 12 )( 20 ) Common Stock 357 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bujarski Robert Joseph 9975 SUMMERS RIDGE ROAD SAN DIEGO, CA92121 Chief Operating Officer Signatures /s/ Phillip S. Askim, attorney-in-fact for Robert J. Bujarski 06/01/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. ( 2 )Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). ( 3 )Vested in full. ( 4 )5,435 shares are vested in full; 1,811 shares will vest on February 4, 2023. ( 5 )3,321 shares are vested in full; the remaining 3,320 shares will vest in equal installments on February 3, 2023 and February 3, 2024. ( 6 )1,467 shares will vest on September 14, 2022; the remaining 1,468 shares will vest in equal installments on September 14, 2023 and September 14, 2024. ( 7 )878 shares are vested in full; 878 shares will vest on February 1, 2023; the remaining 1,758 shares will vest in equal installments on February 1, 2024 and February 1, 2025. ( 8 )12,876 shares will vest in equal installments on January 31, 2023, January 31, 2024, January 31, 2025 and January 31, 2026. ( 9 )Each restricted stock unit represents the right to receive one share of Quidel common stock. ( 10 )Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). ( 11 )3,623 shares will vest on February 4, 2023. ( 12 )Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. ( 13 )1,033 shares will vest on November 18, 2022. ( 14 )3,320 shares will vest in equal installments on February 3, 2023 and February 3, 2024. ( 15 )313 shares will vest on September 14, 2022; the remaining 628 shares will vest in equal installments on September 14, 2023 and September 14, 2024. ( 16 )2,637 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025. ( 17 )389 shares will vest on October 15, 2022; the remaining 1,170 shares will vest in equal installments on October 15, 2023, October 15, 2024 and October 15, 2025. ( 18 )3,219 shares will vest on each of January 31, 2023 and January 31, 2024; 3,220 shares will vest on each of January 31, 2025 and January 31, 2026. ( 19 )6,772 shares will vest on January 31, 2024; 3,386 shares will vest on January 31, 2025; and 3,387 shares will vest on January 31, 2026. ( 20 )357 shares will vest on January 31, 2023.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.